Valeant settles the R&O lawsuit that touched off its specialty pharmacy woes

Valeant's ($VRX) relationship with now-dissolved specialty pharmacy Philidor may be the one that has drawn the most scrutiny from short sellers, investors and regulators. But it was litigation from another specialty pharmacy, R&O, that opened up the controversy in the first place. Now, Valeant has settled that R&O lawsuit, it said Wednesday--but that hardly means it's out of the woods. As the Canadian drugmaker recently disclosed, the SEC is investigating, and sources have told The Wall Street Journal that its Philidor connections are the subject of the probe. Release | More

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.